Prudential Financial Inc. Reduces Position in Thermo Fisher Scientific Inc. $TMO

Prudential Financial Inc. lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 30.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 375,329 shares of the medical research company’s stock after selling 165,457 shares during the period. Prudential Financial Inc. owned 0.10% of Thermo Fisher Scientific worth $152,181,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Thermo Fisher Scientific by 0.9% during the second quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock worth $13,700,154,000 after buying an additional 309,207 shares in the last quarter. Franklin Resources Inc. boosted its position in Thermo Fisher Scientific by 11.3% during the second quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock worth $1,985,759,000 after acquiring an additional 498,238 shares during the last quarter. Amundi grew its stake in Thermo Fisher Scientific by 5.9% in the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock worth $1,426,316,000 after acquiring an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Thermo Fisher Scientific by 2.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock valued at $1,216,612,000 after acquiring an additional 74,971 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after purchasing an additional 329,974 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 2.6%

TMO opened at $587.47 on Friday. The company has a market cap of $220.72 billion, a PE ratio of 33.94, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The firm has a 50 day moving average price of $537.07 and a 200 day moving average price of $473.46.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

TMO has been the subject of several analyst reports. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Wells Fargo & Company lifted their price target on Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Argus raised their target price on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Barclays upped their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, TD Cowen lifted their price target on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Nineteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Insiders Place Their Bets

In other news, COO Michel Lagarde sold 4,638 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $594.42, for a total transaction of $2,756,919.96. Following the sale, the chief operating officer owned 23,480 shares in the company, valued at $13,956,981.60. This trade represents a 16.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Lisa P. Britt sold 1,058 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the transaction, the vice president owned 13,087 shares of the company’s stock, valued at $7,698,558.62. This trade represents a 7.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 41,845 shares of company stock valued at $23,947,352. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.